Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2018;56(4):203-211.
doi: 10.5114/reum.2018.77971. Epub 2018 Aug 31.

Tofacitinib in the treatment of patients with rheumatoid arthritis: position statement of experts of the Polish Society for Rheumatology

Eugeniusz J Kucharz  1 , Marcin Stajszczyk  2 , Anna Kotulska-Kucharz  1 , Bogdan Batko  3 , Marek Brzosko  4 , Sławomir Jeka  5 , Piotr Leszczyński  6   7 , Maria Majdan  8 , Marzena Olesińska  9 , Włodzimierz Samborski  6 , Piotr Wiland  10
Affiliations

Tofacitinib in the treatment of patients with rheumatoid arthritis: position statement of experts of the Polish Society for Rheumatology

Eugeniusz J Kucharz et al. Reumatologia. 2018.

Abstract

Tofacitinib is a newly approved small-molecule targeted synthetic disease-modifying antirheumatic drug. The drug was designed as a selective and specific inhibitor of pro-inflammatory receptor signalling. Tofacitinib inhibits the process of intracellular signalling from the receptor to the cellular nucleus and inhibits the inflammation process via a new pathway (inhibition of the Janus kinases), which is unavailable to biological medicines. Tofacitinib has been approved for use in the treatment of patients with moderate to severe active RA. The drug may be used in combination with methotrexate or another conventional synthetic disease-modifying antirheumatic drug or in monotherapy. The efficacy of tofacitinib has been confirmed in several clinical trials. The drug inhibits radiographic progression of the disease. The innovative mechanism of action of tofacitinib is a noteworthy feature because it offers hope of effective treatment for patients who fail to respond to other drugs. The presented article discusses the mechanism of action and the clinical application of tofacitinib. Tofacitinib represents a new group of disease-modifying antirheumatic drugs that can be placed on an equal footing with biological drugs already available.

Keywords: management; rheumatoid arthritis; tofacitinib.

PubMed Disclaimer

Figures

Fig. 1
Fig. 1
Chemical structure of tofacitinib.
See this image and copyright information in PMC

References

    1. Kucharz EJ. Reumatoidalne zapalenie stawów. In: Puszczewicz MJ, editor. Wielka Interna. Warszawa: Medical Tribune; 2016. pp. 79–95.
    1. Smolen JS, van der Heijde D, Machold KP, et al. Proposal for a new nomenclature of disease-modifying antirheumatic drugs. Ann Rheum Dis. 2014;73:3–5. - PubMed
    1. Kucharz EJ, Stajszczyk M, Batko B, et al. Biopodobne leki biologiczne w reumatologii. Forum Reumatol. 2017;4:191–204.
    1. Smolen JS, Landewé R, Bijlsma J, et al. EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2016 update. Ann Rheum Dis. 2017;76:960–977. - PubMed
    1. Taylor PC, Sullivan E, Wood R, et al. Factors influencing treatment adjustments in rheumatoid arthritis patients – biologic DMARD treatment start and options. Arthritis Rheumatol. 2015;67(Suppl 1) abstract no 2640.

LinkOut - more resources